Approval · Notice of Compliance 28248 · 2022
COSOPT: Notice of Compliance 28248
Issued May 24, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28248
- Date
- May 24, 2022
- Company
- Elvium Life SciencesToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) to the current 2020 PM Master Template and to align the inner and out labels with plain language labelling (PLL) requirements.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COSOPT | Not yet assigned | — |
| COSOPT PRESERVATIVE-FREE | Not yet assigned | — |
Medicinal ingredients
- TIMOLOL MALEATE 5 MG per ML
- DORZOLAMIDE HYDROCHLORIDE 20 MG per ML